Accueil・Liste d'Actions・Compugen Ltd

Compugen Ltd

Ouvert

2.35

Acheter Vendre

Résumé

Variation du prix de l'action

24h

Actuel

Min

2.34

Max

2.37

Chiffres clés
By Trading Economics
Revenu	-65M -7.7M
Ventes	-65M 2.2M
P/E Moyenne du Secteur	6.29 60.149
BPA	-0.08
Marge bénéficiaire	-352.436
Employés	75
EBITDA	-64M -7.7M

Recommandations
By TipRanks
Recommandations	Achat Fort
Prévisions sur 12 Mois	+97.05% upside

Dividendes
By Acuity
Prochains Résultats	3 août 2026

Statistiques du Marché
By TradingEconomics
Capitalisation Boursière	-44M 226M
Ouverture précédente	2.35
Clôture précédente	2.35

Compugen Ltd Graphique

Les performances passées ne sont pas un indicateur fiable des résultats futurs.

Actualités Associées

19 juil. 2026, 23:51 UTC

Bitcoin dips amid crypto volatility, while Ethereum rises; South Korea's GDP trends and geopolitical tensions raise concerns for regional market stability.

19 juil. 2026, 23:51 UTC

"Bitcoin dips as Ethereum rises amid geopolitical tensions and South Korea's GDP data, with key economic indicators on the horizon."

19 juil. 2026, 23:51 UTC

"Bitcoin Declines Amid Mixed Crypto Performance; South Korea's GDP and ASEAN Interest Rate Talks Signal Potential Market Shifts."

19 juil. 2026, 23:51 UTC

Mixed cryptocurrency performance amid geopolitical tensions and economic uncertainties, with South Korea's GDP figures and rising U.S. margin debt raising investor concerns.

19 juil. 2026, 23:51 UTC

Bitcoin is trading lower today, continuing a trend following Friday's declines in U.S. equity markets. It remains above its 20-day moving average.

19 juil. 2026, 23:41 UTC

Canada's New Housing Price Index set for July 24, with a forecasted decline of -0.2% amid cautious market sentiment and ongoing economic pressures.

19 juil. 2026, 23:21 UTC

Upcoming Chicago Fed National Activity Index release on July 23, 2026, may signal U.S. economic growth amidst mixed sentiment and inflation concerns.

19 juil. 2026, 23:21 UTC

Canada's Retail Sales Ex Autos Expected to Rise 0.4% in May Amid Cautious Optimism on Consumer Spending

19 juil. 2026, 23:11 UTC

Correlated Moves

During after-market hours, SGD/CHF is higher, reflecting a slight gain since Friday's close. The asset exhibited notable volatility amid broader macroeconomic trends.

19 juil. 2026, 23:11 UTC

ECB Expected to Maintain Interest Rate at 2.4% Amid Rising Energy Costs and Global Economic Concerns

19 juil. 2026, 23:11 UTC

Euro Area's Deposit Facility Rate Expected to Hold Steady at 0.0225% Amid Cautious Market Sentiment and Geopolitical Tensions

19 juil. 2026, 23:01 UTC

China's Loan Prime Rate Expected to Hold Steady at 3.50% Amid Cautious Economic Sentiment and Geopolitical Tensions Ahead of July Release

19 juil. 2026, 23:01 UTC

China's Loan Prime Rate (LPR) 1Y release on July 20, 2026, forecasted at a cautious 0.03%, amid economic concerns impacting consumer spending and credit demand.

19 juil. 2026, 23:01 UTC

After-market trading for GBP/ZAR shows gains since Friday's close, fluctuating throughout the session and remaining near the upper end of its one-month range.

19 juil. 2026, 23:01 UTC

Macro News

Correlated Moves

GBP/USD declines in after-hours trading as the U.S. dollar strengthens against major currencies, reflecting broader investor sentiment and geopolitical tensions.

19 juil. 2026, 23:01 UTC

GBP/CHF is higher in after-market trading, reaching the upper end of its one-month trading range despite no specific news identified for today's move.

19 juil. 2026, 22:51 UTC

USD/NOK is trading higher in after-market hours, moving from a low to a high since Friday's close, despite remaining below its 20-day moving average.

19 juil. 2026, 22:31 UTC

Japan's Inflation Rate Release on July 23, 2026: Market Eyes Potential Impact of Recent Economic Shifts and Extreme Weather on Monetary Policy.

19 juil. 2026, 22:31 UTC

Japan's Core Inflation Rate Expected to Rise to 1.6% Amid Economic Concerns and Geopolitical Tensions Ahead of July Release

19 juil. 2026, 22:21 UTC

GBP/NOK is higher in after-hours trading, reaching the upper end of its one-month range. No specific news was identified for this price move.

19 juil. 2026, 22:21 UTC

EUR/SEK advanced in after-market trading, reaching a peak above previous levels. The performance contrasts with its position in the one-month trading range.

19 juil. 2026, 22:21 UTC

Mortgage Rates Hit Nine-Month High at 6.65%, Raising Concerns Over Housing Affordability and Consumer Spending Ahead of Upcoming MBA Data Release

19 juil. 2026, 22:21 UTC

Canada's June 2026 Inflation Rate Release Sparks Caution Amid Rising Gas Prices and Mixed Market Expectations

19 juil. 2026, 22:21 UTC

Canada's Inflation Rate Expected to Decrease by 0.002% in June, Signaling Potential Deflationary Pressures Ahead of July Release

19 juil. 2026, 22:21 UTC

Canada's Core Inflation Rate Release on July 20, 2026 Expected to Impact Monetary Policy Amid Ongoing Economic Pressures.

19 juil. 2026, 22:21 UTC

Correlated Moves

Avalanche is declining during Sunday’s session, reflecting broader cryptocurrency market sentiment. The asset remains below its 20-day moving average.

19 juil. 2026, 22:11 UTC

Correlated Moves

Gold/CAD is declining in the ongoing session, continuing a downward trend since Friday's close, with Silver also showing weakness.

19 juil. 2026, 22:11 UTC

Correlated Moves

Gold Ounce vs Euro is trading lower, reflecting a decline since Friday's close, influenced by a drop in Silver prices and macroeconomic factors.

19 juil. 2026, 22:11 UTC

Correlated Moves

Gold/JPY is trading lower, continuing a decline since Friday's close. The asset remains below its 20-day moving average amid broader weakness in precious metals.

19 juil. 2026, 22:11 UTC

Macro News

Crude oil prices are rising amid concerns over shipping route disruptions and escalating U.S.-Iran tensions. Prices have regained momentum above the 20-day moving average.

Comparaison

Variation de prix

Compugen Ltd prévision

Objectif de Prix

By TipRanks

97.05% hausse

Prévisions sur 12 Mois

Moyen 4.67 USD 97.05%

Haut 5 USD

Bas 4 USD

Basé sur 3 analystes de Wall Street proposant des objectifs de prix à 12 mois pour Microsoft Corp. au cours des 3 derniers mois.

Note du Consensus

By TipRanks

Achat Fort

3 ratings

Achat

Maintien

Vente

Basé sur 3 qui ont noté l'action Microsoft Corp. au cours des 3 derniers mois.

Éléments financiers

Frais Généraux et Administratifs

Dépenses d'exploitation

Résultat avant impôt

Ventes

Coût des ventes

Marge brute des ventes

Charges d'intérêt sur la dette

EBITDA

Bénéfice d'exploitation

À Propos Compugen Ltd

Compugen Ltd., a clinical-stage therapeutic discovery and development company, researches, develops, and commercializes therapeutic and product candidates in Israel, the United States, and Europe. The company's immuno-oncology pipeline consists of COM701, an anti-PVRIG antibody that is in Phase I clinical study used for the treatment of solid tumors; COM902, a therapeutic antibody targeting TIGIT, which is in Phase I monotherapy clinical study in patients with advanced malignancies through sequential dose escalations; Bapotulimab, a therapeutic antibody targeting ILDR2 that is in Phase I clinical study in patients with naïve head and neck squamous cell carcinoma; and Rilvegostomig, a novel anti-TIGIT/PD-1 bispecific antibody, which is in Phase II clinical study in patients with advanced or metastatic non-small cell lung cancer. Its therapeutic pipeline also includes early-stage immuno-oncology programs focused to address various mechanisms of immune resistance; and COM503, high affinity antibody, which blocks the interaction between IL-18 binding protein and IL-18. The company has collaboration agreement with Bayer Pharma AG for the research, development, and commercialization of antibody-based therapeutics against the company's immune checkpoint regulators; Bristol-Myers Squibb to evaluate the safety and tolerability of COM701 in combination with Bristol-Myers Squibb's PD-1 immune checkpoint inhibitor Opdivo in patients with advanced solid tumors; and Johns Hopkins School of Medicine to evaluate novel T cell and myeloid checkpoint targets. It has license agreement with AstraZeneca for the development of bi-specific and multi-specific immuno-oncology antibody products; and research collaboration with Johns Hopkins University for myeloid. Compugen Ltd. was incorporated in 1993 and is headquartered in Holon, Israel.